Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
MetadataShow full item record
There is a critical need for blood pressure-lowering strategies that have greater efficacy and minimal side effects. Low-dose combinations hold promise in this regard, but there are few data on very-low-dose therapy. We, therefore, conducted a systematic review and meta-analysis of randomized controlled trials with at least one quarter-dose and one placebo and standard-dose monotherapy arm. A search was conducted of Medline, Embase, Cochrane Registry, Food and Drug Administration, and European Medicinal Agency websites. Data on blood pressure and adverse events were pooled using a fixed-effect model, and bias was assessed using Cochrane risk of bias. The review included 42 trials involving 20 284 participants. Thirty-six comparisons evaluated quarter-dose with placebo and indicated a blood pressure reduction of -4.7/-2.4 mm Hg (P < 0.001). Six comparisons were of dual quarter-dose therapy versus placebo, observing a -6.7/ -4.4 mm Hg (P < 0.001) blood pressure reduction. There were no trials of triple quarter-dose combination versus placebo, but one quadruple quarter-dose study observed a blood pressure reduction of -22.4/-13.1 mm Hg versus placebo (P < 0.001). Compared with standard-dose monotherapy, the blood pressure differences achieved by single (37 comparisons), dual (7 comparisons), and quadruple (1 trial) quarter-dose combinations were +3.7/+2.6 (P < 0.001), +1.3/-0.3 (NS), and -13.1/-7.9 (P < 0.001) mm Hg, respectively. In terms of adverse events, single and dual quarter-dose therapy was not significantly different from placebo and had significantly fewer adverse events compared with standard-dose monotherapy. Quarter-dose combinations could provide improvements in efficacy and tolerability of blood pressure-lowering therapy.
Showing items related by title, author, creator and subject.
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic reviewChow, C.; Thakkar, J.; Bennett, A.; Hillis, G.; Burke, M.; Usherwood, T.; Vo, K.; Rogers, K.; Atkins, E.; Webster, R.; Chou, M.; Dehbi, H.; Salam, A.; Patel, A.; Neal, B.; Peiris, D.; Krum, H.; Chalmers, J.; Nelson, M.; Reid, Christopher; Woodward, M.; Hilmer, S.; Thom, S.; Rodgers, A. (2017)Â© 2017 Elsevier Ltd Background Globally, most patients with hypertension are treated with monotherapy, and control rates are poor because monotherapy only reduces blood pressure by around 9/5 mm Hg on average. There is ...
Lonn, E.; Bosch, J.; López-Jaramillo, P.; Zhu, J.; Liu, L.; Pais, P.; Diaz, R.; Xavier, D.; Sliwa, K.; Dans, A.; Avezum, A.; Piegas, L.; Keltai, K.; Keltai, M.; Chazova, I.; Peters, R.; Held, C.; Yusoff, K.; Lewis, B.; Jansky, P.; Parkhomenko, A.; Khunti, K.; Toff, W.; Reid, Christopher; Varigos, J.; Leiter, L.; Molina, D.; McKelvie, R.; Pogue, J.; Wilkinson, J.; Jung, H.; Dagenais, G.; Yusuf, S.; HOPE-3 Investigators (2016)BACKGROUND: Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its role in persons at intermediate risk ...
Yusuf, S.; Bosch, J.; Dagenais, G.; Zhu, J.; Xavier, D.; Liu, L.; Pais, P.; López-Jaramillo, P.; Leiter, L.; Dans, A.; Avezum, A.; Piegas, L.; Parkhomenko, A.; Keltai, K.; Keltai, M.; Sliwa, K.; Peters, R.; Held, C.; Chazova, I.; Yusoff, K.; Lewis, B.; Jansky, P.; Khunti, K.; Toff, W.; Reid, Christopher; Varigos, J.; Sanchez-Vallejo, G.; McKelvie, R.; Pogue, J.; Jung, H.; Gao, P.; Diaz, R.; Lonn, E.; HOPE-3 Investigators (2016)BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated ...